Welcome to our dedicated page for Apexigen news (Ticker: APGN), a resource for investors and traders seeking the latest updates and insights on Apexigen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apexigen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apexigen's position in the market.
Apexigen, a clinical-stage biopharmaceutical company (NASDAQ: APGN), announced its participation in the Wedbush PacGrow Healthcare Conference on August 9, 2022. The event will feature a panel discussion focused on advancements and challenges in immuno-oncology, scheduled for 2:20 p.m. ET. A webcast of the presentation will be available on Apexigen's website post-event. Apexigen develops innovative antibody-based therapeutics for cancer treatment, particularly leveraging its proprietary APXiMAB discovery platform.
Apexigen, Inc. commenced trading today on the Nasdaq under the ticker APGN after closing its business combination with Brookline Capital Acquisition Corp. The transaction yielded gross proceeds of $19.0 million, integrating funds from BCAC’s trust account and PIPE financing. Apexigen focuses on antibody therapeutics for oncology, with its lead candidate, sotigalimab, in Phase 2 studies showcasing potential in treating various solid tumors. The company aims to leverage its innovative pipeline and strategic partnerships to enhance its market presence.
FAQ
What is the market cap of Apexigen (APGN)?
